Phospholamban: A crucial regulator of cardiac contractility

Nature Reviews Molecular Cell Biology

Volumn 4, Issue 7, 2003, Pages 566-577

  MacLennan, David H ^a   Kranias, Evangelia G ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; ADENOSINE TRIPHOSPHATASE (CALCIUM); BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CONTRACTILE PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; PHOSPHOLAMBAN; RYANODINE RECEPTOR;

BETA ADRENERGIC STIMULATION; EXCITATION CONTRACTION COUPLING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC LINKAGE; GENOTYPE; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; IN VIVO STUDY; KINETICS; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ANIMALS; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; CARDIOMYOPATHY, DILATED; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

MUS MUSCULUS;

EID: 0038464639     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrm1151     Document Type: Review

References (116)

1. Kass, D. A., Hare, J. M. & Georgakopoulos, D. Murine cardiac function: a cautionary tail. Circ. Res. 82, 519-522 (1998).
2. Levitzki, A. From epinephrine to cyclic AMR Science 241, 800-806 (1988).
3. Bers, D. M. Calcium and cardiac rhythms: physiological and palhophysiological. Circ. Res. 90, 14-17 (2002).
4. Simmerman, H. K. & Jones, L. R. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. 78, 921-947 (1998).
5. 2+ conformation.
6. Kimura, Y., Kurzydlowski, K., Tada, M. & MacLennan, D. H. Phospholamban inhibitory function is activated by depolymerization. J. Biol. Chem. 272, 15061-15064 (1997). Scanning mutagenesis of the PLN transmembrane helix shows two faces: one interacts with SERCA, so that mutants remain pentameric but lose Inhibitory function; the other interacts with PLN, so that mutants become monomeric and gain inhibitory function. It is deduced that the PLN monomer is the active inhibitory species.
7. Zhai, J. et al. Cardiac-specific overexpression of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo. J. Biol. Chem. 275, 10538-10544 (2000). Superinhibition of SERCA2a by a PLN mutant results in dilated cardiomyopathy in a mouse model.
8. Zvaritch, E. et al. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility. J. Biol. Chem. 275, 14985-14991 (2000).
9. Haghighi, K. et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J. Biol. Chem. 276, 24145-24152 (2001).
10. Luo, W. et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ. Res. 75, 401-409 (1994). The first clear evidence of the important role of PLN in the regulation of cardiac contractility in a whole animal.
11. Kadambi, J. et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97, 533-539 (1996). Only about 40% of SERCA2a molecules are inhibited by PLN under normal conditions, even though PLN is in molar excess over SERCA2a.
12. Koss, K. L. & Kranias, E. G. Phospholamban: a prominent regulator of myocardial contractility. Circ. Res. 79, 1059-1063 (1996).
13. Minamisawa, S. et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313-322 (1999). PLN ablation can reverse heart failure in a cardiomyopathic mouse model that is induced by a mutation in a structural protein.
14. 2+-ATPase activity and cardiac myocyte contractility. Circulation 100, 974-980 (1999).
15. Hoshijima, M. et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nature Med. 8, 864-871 (2002).
16. Schmitt, J. P. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410-1413 (2003). A human PLN mutation that is associated with heart failure in man inhibits PKA, leading to a lack of PLN phosphorylation and chronic inhibition of SERCA2a.
17. Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy: critical difference between mouse and man. J. Clin. Invest. 111, 869-876 (2003). In contrast to the beneficial effects of PLN ablation in mice, the absence of PLN in man might be associated with heart failure.
18. Kirchberger, M. A., Tada, M., Repke, D. I. & Katz, A. M. Cyclic adenosine 3′,5′-monophosphate-dependent protein kinase stimulation of calcium uptake by canine cardiac microsomes. J. Mol. Cell. Cardiol. 4, 673-680 (1972).
19. Ketz, A. M. Discovery of phospholamban. A personal history. Ann. NY Acad. Sci. 853, 9-19 (1998).
20. Tada, M., Kirchberger, M. A. & Katz, A. M. Phosphorylation of a 22,000-dalton component of the cardiac sarcoplasmic reticulum by adenosine 3′:5′-monophosphate-dependent protein kinase. J. Biol. Chem. 250, 2640-2647 (1975). Identification of PLN as a crucial player in β-adrenergic stimulation of the heart.
21. La Raia, P. J. & Morkin, E. Adenosine 3′,5′-monophosphate dependent membrane phosphorylation: a possible mechanism for the control of microsomal calcium transport in heart muscle. Circ. Res. 35, 298-306 (1974).
22. 2+. J. Biol. Chem. 268, 17018-17025 (1993).
23. 2+-ATPase by phospholamban. Biochem. J. 318, 973-979 (1996).
24. Kranias, E. G. & Solaro, R. J. Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature 298, 182-184 (1982). PLN is phosphorylated when elevated levels of catecholamines stimulate contractility of intact hearts.
25. Wegener, A. D., Simmerman, H. K., Lindemann, J. P. & Jones, L. R. Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to β-adrenergic stimulation. J. Biol. Chem. 264, 11468-11474 (1989).
26. Talosi, L., Edes, L. & Kranias, E. G. Intracellular mechanisms mediating reversal of β-adrenergic stimulation in intact beating hearts. Am. J. Physiol. 264, H791-H797 (1993).
27. 2+-ATPase activity in guinea pig ventricles. J. Biol. Chem. 258, 464-471 (1983).
28. Garvey, J. L., Kranias, E. G. & Solaro, R. J. Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem. J. 249, 709-714 (1988).
29. Mundina-Weilenmann, C., Vittone, L., Ortale, M., de Cingolani, G. C. & Mattiazzi, A. Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. J. Biol. Chem. 271, 33561-33567 (1996).
30. Fujii, J. et al. Complete complementary DNA-derived amino acid sequence of canine cardiac phospholamban. J. Clin. Invest. 79, 301-304 (1987).
31. Odermatt, A. et al. Characterization of the gene encoding human sarcolipin (SLN), a proteolipid associated with SERCA1: absence of structural mutations in five patients with Brody disease. Genomics 45, 541-553 (1997).
32. 2+-ATPase. J. Biol. Chem. 273, 12360-12369 (1998).
33. Mortishire-Smith, R. J. et al. Solution structure of the cytoplasmic domain of phopholamban: phosphorylation leads to a local perturbation in secondary structure. Biochemistry 34, 7603-7613 (1995).
34. Pollesello, P., Annila, A. & Ovaska, M. Structure of the 1-36 amino-terminal fragment of human phospholamban by nuclear magnetic resonance and modeling of the phospholamban pentamer. Biophys. J. 76, 1784-1795 (1999).
35. Lamberth, S. et al. NMR structure of phospholamban. Helvetica Chimica Acta 83, 2141-2152 (2000).
36. Mascioni, A., Karim, C., Barany, G., Thomas, D. D. & Veglia, G. Structure and orientation of sarcolipin in lipid environments. Biochemistry 41, 475-482 (2002).
37. 2+ pump of sarcoplasmic reticulum. Nature 342, 90-92 (1989).
38. Toyoshima, C. & Nomura, H. Structural changes in the calcium pump accompanying the dissociation of calcium. Nature 418, 605-611 (2002).
39. 2+-ATPase of sarcoplasmic reticulum that affect functional association with phospholamban. J. Biol. Chem. 268, 2809-2815 (1993).
40. 2+-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites. J. Biol. Chem. 274, 32855-32862 (1999).
41. 2+-ATPase of cardiac sarcoplasmic reticulum are critical for functional association with phospholamban. J. Biol. Chem. 269, 22929-22932 (1994).
42. 2+-ATPase of sarcoplasmic reticulum. J. Biol. Chem. 269, 3088-3094 (1994).
43. 2+-ATPase through intramembrane interactions. J. Biol. Chem. 271, 21726-21731 (1996).
44. Arkin, I. T. et al. Structural organization of the pentameric transmembrane α-helices of phospholamban, a cardiac ion channel. EMBO J. 13, 4757-4764 (1994).
45. Simmerman, H. K., Kobayashi, Y. M., Autry, J. M. & Jones, L. R. A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure. J. Biol. Chem. 271, 5941-5946 (1996).
46. Adams, P. D., Arkin, I. T., Engelman, D. M. & Brunger, A. T. Computational searching and mutagenesis suggest a structure for the pentameric transmembrane domain of phospholamban. Nature Struct. Biol. 2, 154-162 (1995).
47. 2+ pump and phospholamban in Spodoptera frugiperda (Sf21) cells reveals new insights on ATPase regulation. J. Biol. Chem. 272, 15872-15880 (1997).
48. 2+-ATPase isoform of cardiac sarcoplasmic reticulum. J. Biol. Chem. 273, 14238-14241 (1998).
49. 2+-ATPases. J. Biol. Chem. 272, 28815-28818 (1997).
50. Toyoshima, C., Nakasako, M., Nomura, H. & Ogawa, H. Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution. Nature 405, 647-655 (2000).
51. Knighton, D. R. et al. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 414-420 (1991).
52. Hutter, M. C. et al. A structural model of the complex formed by phospholamban and the calcium pump of sarcoplasmic reticulum obtained by molecular mechanics. Chembiochem. 3, 1200-1208 (2002).
53. 2+-, but not by phospholamban phosphorylation, vanadate, or thapsigargin, and are enhanced by ATP. J. Biol. Chem. 275, 15034-15038 (2000).
54. Luo, W. et al. Phospholamban gene dosage effects in the mammalian heart. Circ. Res. 78, 839-847 (1996).
55. 2+. Am. J. Physiol. 271, C391-C397 (1996).
56. Li, L., Chu, G., Kranias, E. G. & Bers, D. M. Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am. J. Physiol. 274, H1335-H1347 (1998).
57. Lorenz, J. N. & Kranias, E. G. Regulatory effects of phospholamban on cardiac function in intact mice. Am. J. Physiol. 273, H2826-H2831 (1997).
58. Kiss, E. et al. 5-adrenergic regulation of cAMP and protein phosphorylation in phospholamban-knockout mouse hearts. Am. J. Physiol. 272, H785-H790 (1997).
59. Santana, L. F., Gomez, A. M., Kranias, E. G. & Lederer, W. J. Amount of calcium in the sarcoplasmic reticulum: influence on excitation-contraction coupling in heart muscle. Heart Vessels Suppl. 12, 44-49 (1997).
60. 2+ channels in mouse ventricular myocytes. Am. J. Physiol. 272, H606-H612 (1997).
61. Chu, G. et al. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ. Res. 79, 1064-1076 (1996).
62. Desai, K. H., Schauble, E., Luo, W., Kranias, E. & Bernstein, D. Phospholamban deficiency does not compromise exercise capacity. Am. J. Physiol. 276, H1172-H1177 (1999).
63. Slack, J. P. et al. The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J. Mol. Cell. Cardiol. 33, 1031-1040 (2001).
64. Kiriazis, H. et al. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovasc. Res. 53, 372-381 (2002).
65. Cross, H. R., Kranias, E. G., Murphy, E. & Steenbergen, C. Ablation of PLB exacerbates ischemic injury to a lesser extent in female than male mice: protective role of NO. Am. J. Physiol. Heart Circ. Physiol. 284, H683-H690 (2003).
66. Lalli, J., Harrer, J. M., Luo, W., Kranias, E. G. & Paul, R. J. Targeted ablation of the phospholamban gene is assodated with a marked decrease in sensitivity in aortic smooth muscle. Circ. Res. 80, 506-513 (1997).
67. Slack, J. P., Grupp, I. L., Luo, W. & Kranias, E. G. Phospholamban ablation enhances relaxation in the murine soleus. Am. J. Physiol. 273, C1-C6 (1997).
68. Nobe, K., Sutliff, R. L., Kranias, E. G. & Paul, R. J. Phospholamban regulation of bladder contractility: evidence from gene-altered mouse models. J. Physiol. 535, 867-878 (2001).
69. Sutliff, R. L., Hoying, J. B., Kadambi, V. J., Kranias, E. G. & Paul, R. J. Phospholamban is present in endothelial cells and modulates endothelium-dependent relaxation. Evidence from phospholamban gene-ablated mice. Circ. Res. 84, 360-364 (1999).
70. Dash, R. et al. Interactions between phospholamban and β-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103, 889-896 (2001).
71. 2+-handling in failing human myocardium. J. Mol. Cell. Cardiol. 33, 1345-1353 (2001).
72. Colyer, J. & Wang, J. H. Dependence of cardiac sarcoplasmic reticulum calcium pump activity on the phosphorylation status of phospholamban. J. Biol. Chem. 266, 17486-17493 (1991).
73. 2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban. J. Biol. Chem. 275, 12129-12135 (2000).
74. 2+ uptake as a primary cause of heart failure. Cardiovasc. Res. 56, 248-259 (2002).
75. Luo, W. et al. Transgenic approaches to define the functional role of dual site phospholamban phosphorylation. J. Biol. Chem. 273, 4734-4739 (1998).
76. Chu, G. et al. A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to β-agonists. J. Biol. Chem. 275, 38938-38943 (2000).
77. Vittone, L., Mundina-Weilenmann, C., Said, M., Ferrero, P. & Mattiazzi, A. Time course and mechanisms of phosphorylation of phospholamban residues in ischemia-reperfused rat hearts. Dissociation of phospholamban phosphorylation pathways. J. Mol. Cell. Cardiol. 34, 39-50 (2002).
78. Hagemann, D. et al. Frequency-encoding Thr17 phospholamban phesphorylation is independent of Ser16 phosphorylation in cardiac myocytes. J. Biol. Chem. 275, 22532-22536 (2000).
79. Beuckelmann, D. J., Nabauer, M. & Erdmann, E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85, 1046-1055 (1992).
80. 2+ transient of failing human ventricular myocytes. Circ. Res. 84, 435-444 (1999).
81. 2+-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434-442 (1994).
82. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92, 3220-3228 (1995).
83. Frank, K., Bolck, B., Bavendiek, U., & Schwinger, R. H. Frequency dependent force generation correlates with sarcoplasmic calcium ATPase activity in human myocardium. Basic Res. Cardiol. 93, 405-411 (1998).
84. 2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 90, 653-657 (1994).
85. Meyer, M. et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92, 778-784 (1995).
86. 2+-sensitivity of SERCA2a in failing human myocardium due to reduced serine-16 phospholamban phosphorylation. J. Mol. Cell. Cardiol. 31, 479-491 (1999).
87. 2+ transients. Circulation 96, 400-403 (1997).
88. del Monte, F. et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100, 2308-2311 (1999).
89. Miyamoto, M. I. et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc. Natl Acad. Sci. USA 97, 793-798 (2000).
90. 2+-ATPase in a rat model of heart failure. Circulation 104, 1424-1429 (2001).
91. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J. Clin. Invest. 100, 380-389 (1997).
92. 2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ. Res. 83, 1205-1214 (1998).
93. Eizema, K. et al. Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation 101, 2193-2199 (2000).
94. del Monte, F., Harding, S. E., Dec, G. W., Gwathmey, J. K. & Hajjar, R. J. Targeting phospholamban by gene transfer in human heart failure. Circulation 105, 904-907 (2002).
95. Sato, Y. et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J. Biol. Chem. 278, 9392-9399 (2001).
96. Freeman, K. et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J. Clin. Invest. 107, 967-974 (2001).
97. Song, Q. et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J. Clin. Invest. 111, 859-867 (2003).
98. Fink, M. A. et al. AKAP-mediated targeting of protein kinase a regulates contractility in cardiac myocytes. Circ. Res. 88, 291-297 (2001).
99. Pieske, B. et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 99, 1802-1809 (1999).
100. MacLennan, D. H. & Reithmeier, R. A. Ion tamers. Nature Struct. Biol. 5, 409-411 (1998).
101. Zot, A. S. & Potter, J. D. Structural aspects of troponin-tropomyosin regulation of skeletal muscle contraction. Annu. Rev. Biophys. Biophys. Chem. 16, 535-559 (1987).
102. 2+ signalling and muscle disease. Eur. J. Biochem. 267, 5291-5297 (2000).
103. 2+ release channels. Am. J. Med. 104, 470-486 (1998).
104. Priori, S. G. et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103, 196-200 (2001).
105. Laitinen, P. J. et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 103, 485-490 (2001).
106. Postma, A. V. et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ. Res. 91, e21-e26 (2002).
107. 2+ pump, cause Darier disease. Nature Genet. 21, 271-277 (1999).
108. Wawrzynow, A. et al. Sarcolipin, the 'proteolipid' of skeletal muscle sarcoplasmic reticulum, is a unique, amphipathic, 31-residue peptide. Arch. Biochem. Biophys. 298, 620-623 (1992).
109. Gayan-Ramirez, G., Vanzeir, L., Wuytack, F. & Decramer, M. Corticosteroids decrease mRNA levels of SERCA pumps, whereas they increase sarcolipin mRNA in the rat diaphragm. J. Physiol. 524, 387-397 (2000).
110. Minamisawa, S. et al. Atrial-specific expression of sarcolipin is regulated during development and hypertrophic remodeling. J. Biol. Chem. 278, 9570-9575 (2003).
111. 2+ uptake and impairs contractile function. J. Biol. Chem. 277, 44740-44746 (2002).
112. 2+-ATPases (SERCAs). J. Biol. Chem. 277, 26725-26728 (2002).
113. 2+-ATPase (SERCA1a) by binding to transmembrane helices alone or in association with phospholamban. Proc. Natl Acad. Sci. USA 100, 5040-5045 (2003).
114. 2+-dependent ATPase of the sarcoplasmic reticulum. Annu. Rev. Biochem. 48, 275-293 (1979).
115. Stokes, D. L. & Green, N. M. Structure and function of the calcium pump. Annu. Rev. Biophys. Biomol. Struct. 32, 445-468 (2003).
116. Cornea, R. L., Jones, L. R., Autry, J. M. & Thomas, D. D. Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. Biochemistry 36, 2960-2967 (1997).